Nutrients (Apr 2023)
Association of Serum Albumin Levels and Long-Term Prognosis in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease
- Hirokazu Takahashi,
- Miwa Kawanaka,
- Hideki Fujii,
- Michihiro Iwaki,
- Hideki Hayashi,
- Hidenori Toyoda,
- Satoshi Oeda,
- Hideyuki Hyogo,
- Asahiro Morishita,
- Kensuke Munekage,
- Kazuhito Kawata,
- Tsubasa Tsutsumi,
- Koji Sawada,
- Tatsuji Maeshiro,
- Hiroshi Tobita,
- Yuichi Yoshida,
- Masafumi Naito,
- Asuka Araki,
- Shingo Arakaki,
- Takumi Kawaguchi,
- Hidenao Noritake,
- Masafumi Ono,
- Tsutomu Masaki,
- Satoshi Yasuda,
- Eiichi Tomita,
- Masato Yoneda,
- Akihiro Tokushige,
- Yoshihiro Kamada,
- Shinichiro Ueda,
- Shinichi Aishima,
- Yoshio Sumida,
- Atsushi Nakajima,
- Takeshi Okanoue,
- Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)
Affiliations
- Hirokazu Takahashi
- Liver Center, Saga Medical School, Saga University, Saga 849-8501, Japan
- Miwa Kawanaka
- Department of General Internal Medicine2, Kawasaki Medical Center, Okayama 700-8505, Japan
- Hideki Fujii
- Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 558-8585, Japan
- Michihiro Iwaki
- Division of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan
- Hideki Hayashi
- Department of Gastroenterology and Hepatology, Gifu Municipal Hospital, Gifu 500-8323, Japan
- Hidenori Toyoda
- Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki 503-8502, Japan
- Satoshi Oeda
- Liver Center, Saga Medical School, Saga University, Saga 849-8501, Japan
- Hideyuki Hyogo
- Hyogo Life Care Clinic Hiroshima, Hiroshima 732-0823, Japan
- Asahiro Morishita
- Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan
- Kensuke Munekage
- Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi 783-8505, Japan
- Kazuhito Kawata
- Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Shizuoka 431-3192, Japan
- Tsubasa Tsutsumi
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
- Koji Sawada
- Liver Disease Care Unit, Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8802, Japan
- Tatsuji Maeshiro
- First Department of Internal Medicine, University of the Ryukyus Hospital, 207 Uehara, Nishihara, Nakagami, Okinawa 903-0215, Japan
- Hiroshi Tobita
- Department of Hepatology, Shimane University Hospital, 89-1 Enya-cho, Izumo 693-8501, Japan
- Yuichi Yoshida
- Department of Gastroenterology and Hepatology, Suita Municipal Hospital, Osaka 564-8567, Japan
- Masafumi Naito
- Department of Gastroenterology and Hepatology, Suita Municipal Hospital, Osaka 564-8567, Japan
- Asuka Araki
- Department of Hepatology, Shimane University Hospital, 89-1 Enya-cho, Izumo 693-8501, Japan
- Shingo Arakaki
- First Department of Internal Medicine, University of the Ryukyus Hospital, 207 Uehara, Nishihara, Nakagami, Okinawa 903-0215, Japan
- Takumi Kawaguchi
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
- Hidenao Noritake
- Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Shizuoka 431-3192, Japan
- Masafumi Ono
- Division of Innovative Medicine for Hepatobiliary & Pancreatology, Faculty of Medicine, Kagawa University, Kita 761-0793, Japan
- Tsutomu Masaki
- Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan
- Satoshi Yasuda
- Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki 503-8502, Japan
- Eiichi Tomita
- Department of Gastroenterology and Hepatology, Gifu Municipal Hospital, Gifu 500-8323, Japan
- Masato Yoneda
- Division of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan
- Akihiro Tokushige
- Department of Clinical Pharmacology and Therapeutics, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan
- Yoshihiro Kamada
- Department of Advanced Metabolic Hepatology, Osaka University Graduate School of Medicine, 1-7, Yamadaoka, Suita 565-0871, Japan
- Shinichiro Ueda
- Department of Clinical Pharmacology and Therapeutics, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan
- Shinichi Aishima
- Department of Pathology and Microbiology, Faculty of Medicine, Saga University, Saga 849-8501, Japan
- Yoshio Sumida
- Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Nagakute 480-1195, Japan
- Atsushi Nakajima
- Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 558-8585, Japan
- Takeshi Okanoue
- Hepatology Center, Saiseikai Suita Hospital, Suita 564-0013, Japan
- Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)
- DOI
- https://doi.org/10.3390/nu15092014
- Journal volume & issue
-
Vol. 15,
no. 9
p. 2014
Abstract
The relationship between baseline serum albumin level and long-term prognosis of patients with nonalcoholic fatty liver disease (NAFLD) remains unknown. This is a sub-analysis of the CLIONE (Clinical Outcome Nonalcoholic Fatty Liver Disease) study. The main outcomes were: death or orthotopic liver transplantation (OLT), liver-related death, and liver-related events (hepatocellular carcinoma [HCC], decompensated cirrhosis, and gastroesophageal varices/bleeding). 1383 Japanese patients with biopsy-confirmed NAFLD were analyzed. They were divided into 3 groups based on serum albumin: high (>4.0 g/dL), intermediate (3.5–4.0 g/dL), and low (p p < 0.001). Among biopsy-confirmed NAFLD patients, those with intermediate or low serum albumin had a significantly higher risk of death or OLT than those with high serum albumin.
Keywords
